Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
For Research Purposes Only
Out of StockPE-22-28
Third-Party TestedPurity Standards
Total
$34.99Size
Quantity
1
Bundle & Save
Molecular Profile
Molecular Profile
Type
Synthetic heptapeptide (spadin-derived fragment)
Molecular formula
C₃₅H₅₅N₁₁O₉
Molecular weight
773.89 Da
CAS number
1801959-12-5
Amino acids
7
Sequence
Gly-Val-Ser-Trp-Gly-Leu-Arg
Modification
None (linear peptide)
Mechanism & Target Class
Mechanism & Target Class
PE-22-28 is a selective inhibitor of the TREK-1 (KCNK2) two-pore-domain potassium channel. TREK-1 is a background K⁺ channel that contributes to stabilizing neuronal resting membrane potential; blocking it reduces this stabilization and alters cell excitability. Patch-clamp recordings in human TREK-1–expressing cell lines show that PE-22-28 inhibits TREK-1 current; comparative assays of the parent spadin peptide in the same system indicate lower inhibitory activity, motivating the truncation strategy that produced this fragment. PE-22-28's compact structure—7 residues with a hydrophobic tryptophan and a basic arginine—is structurally consistent with binding near the extracellular pore of TREK-1. In selectivity panels, PE-22-28 did not produce significant current inhibition at the closely related K2P channels TREK-2 or TRAAK. PE-22-28 is therefore characterized as a selective peptide antagonist of a neuronal two-pore K⁺ channel.
Storage & Handling
Storage & Handling
Lyophilized
–20 °C
store dry and protected from moisture.
No long-term stability data are published for this peptide; general small-peptide handling practices (sealed, dry, minimize freeze–thaw) apply.
References
References
Reviews
- 1
Djillani A, Mazella J, Heurteaux C, Borsotto M. (2019). Frontiers in Pharmacology
- 2
Borsotto M, Veyssiere J, Moha ou Maati H, Devader C, Maurin Y, et al. (2015). British Journal of Pharmacology
Reviews
- 3
Djillani A, Pietri M, Mazella J, Heurteaux C, Borsotto M. (2019). Pharmacology & Therapeutics
- 4
Mazella J, Borsotto M, Heurteaux C. (2019). Frontiers in Pharmacology
Clinical
- 5
Devader C, Roulot M, Moréno S, et al. (2017). Journal of Affective Disorders
- 6
Roulot M, Minelli A, Bortolomasi M, et al. (2018). Neuropsychiatric Disease and Treatment
- 7
Buttenschøn HN, Nielsen M, Glerup S, Mors O. (2018). Acta Neuropsychiatrica
Primary research
- 8
Daziano G, Blondeau N, Béraud-Dufour S, Abderrahmani A, Rovère C, Heurteaux C, Mazella J, Lebrun P, Coppola T. (2021). Pharmacological Research
- 9
Pietri M, Djillani A, Mazella J, Borsotto M, Heurteaux C. (2019). Neuropharmacology
- 10
Djillani A, Pietri M, Moreno S, Heurteaux C, Mazella J, Borsotto M. (2017). Frontiers in Pharmacology
- 11
Mazella J, Pétrault O, Lucas G, et al. (2010). PLoS Biology
- 12
Moha ou Maati H, Veyssière J, Labbal F, Coppola T, et al. (2012). Neuropharmacology
- 13
Veyssière J, Moha ou Maati H, Mazella J, Gaudriault G, Moreno S, Heurteaux C, Borsotto M. (2015). Psychopharmacology
- 14
Moreno S, Devader CM, Pietri M, Borsotto M, Heurteaux C, Mazella J. (2018). Frontiers in Pharmacology
- 15
Devader C, Khayachi A, Veyssière J, et al. (2015). British Journal of Pharmacology
- 16
Hivelin C, Béraud-Dufour S, Devader C, et al. (2016). Journal of Diabetes Research
- 17
Ma R, Lewis A. (2020). Frontiers in Pharmacology
- 18
Wu F, Sun H, Gong W, Li X, Pan Z, Shan H, Zhang Z. (2021). CNS Neuroscience & Therapeutics
- 19
Wang W, Kiyoshi CM, Du Y, et al. (2020). Molecular Neurobiology
- 20
Kim A, Jung HG, Kim YE, et al. (2019). International Journal of Molecular Sciences
Primary Database
Primary Database
Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.
